leisure time -WSS

leisure time

author：knowledge 2025-10-01 11:35:02 - browse：62

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Impact of Dobbs ruling felt at reproductive medicine meeting

hotspot

WSS

STAT Summit: Michael J. Fox on progress in Parkinson's research

CDC advisory panel says seniors 'may' get RSV vaccine

As pharma fights Medicare drug negotiation, hospitals, docs silent

Lawmakers consider Medicare pay reforms for doctors

How a symptom of dementia informs our understanding of creativity

Pharmacists can make shortage drugs, but at what cost?

Wikipedia

leisure time

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Why more medical students aren't specializing in primary care

Apple is now the first public company to be valued at $3 trillion

STAT Readout Newsletter: Today's biggest biotech updates

How one medical school became remarkably diverse

Impact of Dobbs ruling felt at reproductive medicine meeting

Medical leaders decry Supreme Court decision on affirmative action

Eli Lilly expects to double planned employment in Boston center

Jerome Adams on the need for new antivirals for Covid

Researchers explore possible ties between long Covid, menopause

hotspot

Winners, losers from Medicare’s list of drugs subject to price talks

Radiation, mainstay of cancer treatment, begins a fade

Appeals court upholds limits to abortion pill

Solve the antibiotic resistance crisis with preventive drugs

FDA gives detailed accounting of AI

First Opinion Podcast: Long Covid needs a new approach

Wikipedia

hotspot

hotspot

hotspot